<code id='5005961ECF'></code><style id='5005961ECF'></style>
    • <acronym id='5005961ECF'></acronym>
      <center id='5005961ECF'><center id='5005961ECF'><tfoot id='5005961ECF'></tfoot></center><abbr id='5005961ECF'><dir id='5005961ECF'><tfoot id='5005961ECF'></tfoot><noframes id='5005961ECF'>

    • <optgroup id='5005961ECF'><strike id='5005961ECF'><sup id='5005961ECF'></sup></strike><code id='5005961ECF'></code></optgroup>
        1. <b id='5005961ECF'><label id='5005961ECF'><select id='5005961ECF'><dt id='5005961ECF'><span id='5005961ECF'></span></dt></select></label></b><u id='5005961ECF'></u>
          <i id='5005961ECF'><strike id='5005961ECF'><tt id='5005961ECF'><pre id='5005961ECF'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          leisure time

          author:explore    - browse:668
          Darron Cummings/AP

          In a surprise move, the Food and Drug Administration has called for a meeting of outside advisers to discuss whether an Alzheimer’s drug from Eli Lilly should be approved, even as many outsiders expected the medicine to receive regulatory clearance this month.

          The drug, donanemab, succeeded in its Phase 3 trial, resulting in a 35% slowing of Alzheimer’s disease progression versus placebo. But Lilly on Friday said that the FDA expects to call a meeting of an advisory committee to review the trial, saying that the agency had told the company “it wants to further understand topics related to evaluating the safety and efficacy of donanemab, including the safety results in donanemab-treated patients and the efficacy implications of the unique trial design” of the study.

          advertisement

          A date for the meeting has not been set yet.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time